Micro E-mini S&P 500 Futures (MED)

Medifast Stock (NYSE:MED), Trade Ideas

Medifast

Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AMPL

ATCH

AVGR

BFRI

BLCO

CPOP

EFOI

GBNH

GRMN

HCKT

IOVA

JANX

LIVN

MOTS

MTTR

PANW

PLAB

RAPT

SEDG

SEED

SISI

SNCR

SOGP

TDOC

THRM

TRTX

UCAR

VTYX

WTTR

Shares of  International Flavors &amp; Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly dividend approximately 50% to 40 cents per share.

Why International Flavors &amp; Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pre-Market Outlook

CALT

CRWD

HSBC

KEYS

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 70 points on Wednesday.

Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

BLBX

CALM

CCCC

DESP

EOSE

INAB

IOAC

IPDN

JBLU

LPTV

MYNA

NEPH

NXTP

PCSA

REVG

RSLS

SPRC

STTK

SVMH

TCBP

TTWO

VRTX

WHLR

WLGS

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance.

The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million.

Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Medifast Inc

MediBloc

Medacoin

MEDARO MINING CORP by Medaro Mining Corp.

Medaro Mining Corp

MEDICAL IMAGING CORP by Medical Imaging Corp.

Medical Imaging Corp

Medies

Medacta Group SA

MEDX HOLDINGS INC by MedX Holdings, Inc.

Harbor ETF Trust Harbor Health Care ETF

MEDIPHARM LABS CORP by Medipharm Labs Corporation

MediPharm Labs Corp

Medios AG

Medpace Holdings Inc

Trxade Health Inc

MEDIATECHNICS CORP by MediaTechnics Corp.

MediaTechnics Corp

Medivolve Inc

Horizon Kinetics Medical ETF

MEDEXUS PHARMS INC by Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc

Medifast's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) short percent of float has risen 5.78% since its last report. The company recently reported that it has 2.05 million shares sold short, which is 28.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medifast Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711976413_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medifast has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Medifast's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medifast's peer group average for short interest as a percentage of float is 5.38%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(MED) - Analyzing Medifast's Short Interest

On March 06, 2024, Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) will distribute a dividend payout of $0.06 per share, equating to an annualized dividend yield of 1.38%. Shareholders who owned the stock before the ex-dividend date on February 23, 2024 will receive this payout.
<h3>Nu Skin Enterprises Recent Dividend Payouts</h3>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style><table>
<thead>
<tr>
<th>Ex-Date</th>
<th style="text-align: right;">Payments per year</th>
<th>Dividend</th>
<th>Yield</th>
<th>Announced</th>
<th>Record</th>
<th>Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024-02-23</td>
<td style="text-align: right;">4</td>
<td>$0.06</td>
<td>1.38%</td>
<td>2024-02-14</td>
<td>2024-02-26</td>
<td>2024-03-06</td>
</tr>
<tr>
<td>2023-11-22</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>8.21%</td>
<td>2023-11-01</td>
<td>2023-11-24</td>
<td>2023-12-06</td>
</tr>
<tr>
<td>2023-08-24</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>5.31%</td>
<td>2023-08-01</td>
<td>2023-08-25</td>
<td>2023-09-06</td>
</tr>
<tr>
<td>2023-05-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.91%</td>
<td>2023-05-03</td>
<td>2023-05-26</td>
<td>2023-06-07</td>
</tr>
<tr>
<td>2023-02-24</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.6%</td>
<td>2023-02-15</td>
<td>2023-02-27</td>
<td>2023-03-08</td>
</tr>
<tr>
<td>2022-11-23</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.93%</td>
<td>2022-11-02</td>
<td>2022-11-25</td>
<td>2022-12-07</td>
</tr>
<tr>
<td>2022-08-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.43%</td>
<td>2022-08-04</td>
<td>2022-08-26</td>
<td>2022-09-07</td>
</tr>
<tr>
<td>2022-05-26</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.45%</td>
<td>2022-05-04</td>
<td>2022-05-27</td>
<td>2022-06-08</td>
</tr>
<tr>
<td>2022-02-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.1%</td>
<td>2022-02-16</td>
<td>2022-02-28</td>
<td>2022-03-09</td>
</tr>
<tr>
<td>2021-11-24</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>3.78%</td>
<td>2021-11-03</td>
<td>2021-11-26</td>
<td>2021-12-08</td>
</tr>
<tr>
<td>2021-08-26</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>2.8%</td>
<td>2021-08-04</td>
<td>2021-08-27</td>
<td>2021-09-08</td>
</tr>
<tr>
<td>2021-05-27</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>2.92%</td>
<td>2021-05-05</td>
<td>2021-05-28</td>
<td>2021-06-09</td>
</tr>
</tbody>
</table>
Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) surpassing it with a higher annualized dividend yield of 17.00%.
<h3>Analyzing Nu Skin Enterprises Financial Health</h3>
Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. 
<h3>YoY Growth in Dividend Per Share</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709737512_0.png" alt="dividend chart graph" />
Investors witnessed an upward trajectory in the company's dividend per share between 2020 and 2023. The dividend per share rose from $1.50 to $1.56, indicating the company's dedication to enhancing shareholder value through increased dividends.
<h3>YoY Earnings Growth For Nu Skin Enterprises</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709737512_1.png" alt="earning chart graph" />
From 2020 to 2023, Nu Skin Enterprises experienced a decrease in earnings per share, dropping from $2.97 to $2.36. This declining earnings trend may be worrisome for income-seeking investors, as it indicates a potential impact on the company's ability to sustain or increase its cash dividend payouts. Further analysis is necessary to understand the underlying reasons for this decrease.
<h3>Recap</h3>
In this article, we explore the recent dividend payout of Nu Skin Enterprises and its significance for shareholders. The company has decided to distribute a dividend of $0.06 per share today, which equates to an annualized dividend yield of 1.38%.
Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast surpassing it with a higher annualized dividend yield of 17.00%.
With dividend per share increasing and earnings per share decreasing from 2020 to 2023, Nu Skin Enterprises seems to be emphasizing the distribution of profits to investors despite the decline in profitability.
To stay informed about changes in financials or dividend disbursements, investors should pay close attention to the company's performance in the upcoming quarters.
[See current stock movements Nu Skin Enterprises on Benzinga.](https://www.benzinga.com/quote/Nu Skin Enterprises (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>))
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dividends

Navigating Challenges and Investor Rewards: Nu Skin Enterprises Ensures Steady Distribution amidst Changing Profits

Shares of International Flavors &amp; Fragrances Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iff#NYSE">IFF</a>) fell during Wednesday&rsquo;s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly dividend approximately 50% to 40 cents per share.
International Flavors &amp; Fragrances shares dipped 8.4% to $75.11 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Greenbrook TMS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbnh#NASDAQ">GBNH</a>) climbed 120.8% to $0.4351. Greenbrook TMS raised $2.5 million in debt financing.</li>
<li>Emergent BioSolutions Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ebs#NYSE">EBS</a>) gained 84% to $2.8050. Emergent BioSolutions appointed Joseph Papa as President and CEO, effective Feb. 21, 2024.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) gained 77.2% to $5.30. Traders circulated unconfirmed analyst comments suggesting co might be the next big weight loss drug citing a new publication showing NLRP3 has significant weight loss similar to GLP-1.</li>
<li>Sound Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sogp#NASDAQ">SOGP</a>) shares rose 63.1% to $4.60. Sound Group announced the launch of new AI-powered applications.</li>
<li>Motus GI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mots#NASDAQ">MOTS</a>) shares rose 59.4% to $1.04 after the company was granted U.S. Patent #11904085 for &#39;Systems And Methods For Cleaning A Colon.&#39;</li>
<li>Origin Agritech Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seed#NASDAQ">SEED</a>) gained 34% to $3.11. Origin Agritech increased revenue by 77% year-over-year for the fiscal year ended Sep. 30, 2023.</li>
<li>Gentherm Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thrm#NASDAQ">THRM</a>) shares jumped 24.7% to $61.48 after the company reported better-than-expected fourth-quarter financial results and issued guidance.</li>
<li>RAPT Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rapt#NASDAQ">RAPT</a>) gained 24% to $8.52.</li>
<li>Energy Focus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/efoi#NASDAQ">EFOI</a>) shares jumped 23.4% to $1.7050.</li>
<li>MediaAlpha, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/max#NYSE">MAX</a>) rose 19% to $18.80 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Janux Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/janx#NASDAQ">JANX</a>) gained 18% to $11.75. Janux Therapeutics will host virtual event on Feb. 26th, 2024, at 4:30PM ET to discuss updated clinical data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iova#NASDAQ">IOVA</a>) rose 15.9% to $13.95.</li>
<li>TPG RE Finance Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/trtx#NYSE">TRTX</a>) jumped 12.9% to $6.24 after the company reported fourth-quarter financial results.</li>
<li>Garmin Ltd.(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grmn#NYSE">GRMN</a>) rose 12.2% to $137.72 after the company reported fourth-quarter financial results and issued FY24 revenue guidance above estimates, recommended boosting annual dividend and authorized share buyback.</li>
<li>Select Water Solutions, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wttr#NYSE">WTTR</a>) gained 11.7% to $8.77 following strong earnings.</li>
<li>The Hackett Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hckt#NASDAQ">HCKT</a>) surged 11.2% to $25.48 following upbeat results.</li>
<li>LivaNova PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/livn#NASDAQ">LIVN</a>) jumped 8.8% to $57.28 following upbeat earnings.</li>
<li>EQT Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eqt#NYSE">EQT</a>) gained 8.8% to $36.69.</li>
<li>Wix.com Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wix#NASDAQ">WIX</a>) gained 8.6% to $136.15 following fourth-quarter results.</li>
<li>Bausch + Lomb Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/blco#NYSE">BLCO</a>) gained 8.6% to $15.84 after reporting quarterly results.</li>
<li>Wix.com Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wix#NASDAQ">WIX</a>) gained 8.2% to $135.56 following fourth-quarter results.</li>
<li>NeoGenomics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neo#NASDAQ">NEO</a>) rose 7.4% to $15.78 after the company reported better-than-expected fourth-quarter financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Toll Brothers, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tol#NYSE">TOL</a>) gained 6.6% to $110.42 after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance above estimates.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>AtlasClear Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atch#NYSE">ATCH</a>) shares tumbled 41% to $1.19.</li>
<li>Shineco, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sisi#NASDAQ">SISI</a>) dipped 33.4% to $1.53 after gaining around 56% on Tuesday.</li>
<li>Synchronoss Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sncr#NASDAQ">SNCR</a>) fell 32.2% to $8.30.</li>
<li>U Power Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ucar#NASDAQ">UCAR</a>) dipped 30% to $0.0710 after the company received a delisting notice from the Nasdaq Stock Market due to its ordinary shares&rsquo; closing bid price falling below $0.10 for ten consecutive trading days, as per the Low Priced Stocks Rule.</li>
<li>MoneyHero Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mny#NASDAQ">MNY</a>) fell 28% to $2.2259.</li>
<li>Community Health Systems, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cyh#NYSE">CYH</a>) fell 27.3% to $2.9350 after the company reported fourth-quarter financial results.</li>
<li>Palo Alto Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/panw#NASDAQ">PANW</a>) shares dipped 26.2% to $270.29 after the company issued third-quarter guidance below estimates.</li>
<li>Teladoc Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) shares fell 25.3% to $15.31 after the company reported mixed fourth-quarter financial results and issued weak guidance.</li>
<li>Unisys Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>) fell 24.5% to $5.88 after the company reported quarterly financial results.</li>
<li>Pop Culture Group Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cpop#NASDAQ">CPOP</a>) fell 21.3% to $5.66 after jumping 171% on Tuesday.</li>
<li>Amplitude, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ampl#NASDAQ">AMPL</a>) fell 16.6% to $11.73 after the company reported mixed fourth-quarter financial results and issued weak guidance.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sedg#NASDAQ">SEDG</a>) shares fell 15.7% to $71.20 after the company reported mixed fourth-quarter financial results.</li>
<li>Matterport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mttr#NASDAQ">MTTR</a>) shares fell 15.4% to $2.1450 after the company posted weak quarterly sales and issued downbeat forecast.</li>
<li>Zscaler, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zs#NASDAQ">ZS</a>) fell 14.8% to $212.15.</li>
<li>Medifast, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/med#NYSE">MED</a>) declined 14.3% to $41.95 after the company issued weak guidance.</li>
<li>Avinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avgr#NASDAQ">AVGR</a>) shares fell 14.3% to $4.57 after surging 83% on Tuesday.</li>
<li>Photronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plab#NASDAQ">PLAB</a>) fell 13% to $27.17 after the company reported first-quarter financial results below estimates.</li>
<li>Workiva Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wk#NYSE">WK</a>) fell 12.3% to $82.55 following quarterly results.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) fell 11.4% to $0.5582.</li>
<li>Biofrontera Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfri#NASDAQ">BFRI</a>) shares fell 6.1% to $1.0794. Biofrontera shares jumped 53% on Tuesday after the company announced a private placement of up to $16 million priced at the market per Nasdaq rules.</li>
<li>Sprout Social, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spt#NASDAQ">SPT</a>) shares declined 5.4% to $61.01 after the company reported fourth-quarter financial results and issued guidance.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37237721/bitcoin-falls-below-51-000-starknet-becomes-top-loser"> Bitcoin Falls Below $51,000; Starknet Becomes Top Loser</a>

Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) with a Neutral and lowers the price target from $67 to $40.

Price Target

Analyst Ratings

DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $40

WIIM

Medifast shares are trading lower after the company issued weak guidance.

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 70 points on Wednesday.
Shares of Palo Alto Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/panw#NASDAQ">PANW</a>) fell sharply in today&rsquo;s pre-market trading after the company issued third-quarter <a href="https://www.benzinga.com/news/earnings/24/02/37223409/palo-alto-networks-q2-earnings-eps-beat-revenue-up-19-soft-guidance-and-more">guidance below estimates</a>.
Palo Alto&rsquo;s fiscal second-quarter revenue increased 19% year-over-year to $1.98 billion, which beat the consensus estimate of $1.97 billion, according to Benzinga Pro. The company reported quarterly earnings of $1.46 per share, which beat analyst estimates of $1.30 per share.
Palo Alto sees fiscal third-quarter revenue of $1.95 billion to $1.98 billion versus estimates of $2.04 billion. The company expects third-quarter adjusted earnings to be between $1.24 and $1.26 per share versus estimates of $1.29 per share.
Palo Alto Networks shares tumbled 22.1% to $285.06 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Teladoc Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) shares dipped 20.8% to $16.22 in pre-market trading after the company reported mixed fourth-quarter financial results and issued weak guidance.</li>
<li>Community Health Systems, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cyh#NYSE">CYH</a>) fell 18.3% to $3.30 in pre-market trading after the company reported fourth-quarter financial results.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sedg#NASDAQ">SEDG</a>) shares fell 16% to $70.90 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li>Matterport, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mttr#NASDAQ">MTTR</a>) shares declined 12.6% to $2.22 in pre-market trading after the company posted weak quarterly sales and issued downbeat forecast.</li>
<li>Calliditas Therapeutics AB (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calt#NASDAQ">CALT</a>) fell 9.3% to $18.98 in pre-market trading following quarterly results.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) shares fell 9.2% to $294.00 in pre-market trading.</li>
<li>Sprout Social, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spt#NASDAQ">SPT</a>) fell 9.2% to $58.50 in pre-market trading after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Zscaler, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zs#NASDAQ">ZS</a>) fell 9.2% to $226.15 in pre-market trading.</li>
<li>HSBC Holdings plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hsbc#NYSE">HSBC</a>) fell 7.6% to $37.73 in pre-market trading following fourth-quarter results.</li>
<li>Medifast, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/med#NYSE">MED</a>) fell 7.3% to $45.36 in pre-market trading after the company issued weak guidance.</li>
<li>Keysight Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/keys#NYSE">KEYS</a>) declined 6.8% to $144.00 in pre-market trading after the company issued second-quarter EPS and revenue guidance below estimates.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37229881/investor-sentiment-falls-further-fear-greed-index-in-greed-zone"> Investor Sentiment Falls Further; Fear &amp; Greed Index In &#39;Greed&#39; Zone </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Guidance

MEDIFAST INC Sees Q1 2024 EPS $0.25-$0.95 Vs $1.50 Est.l Revenue $155M-$175M Vs $205.786M Est.

Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Medifast beat estimated earnings by 13.54%, reporting an EPS of $1.09 versus an estimate of $0.96.
Revenue was down $146.23 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $1.06 which was followed by a 2.5% drop in the share price the next day.
Here's a look at Medifast's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.06</td>
<td>1.44</td>
<td>2.40</td>
<td>2.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.12</td>
<td>2.77</td>
<td>3.67</td>
<td>3.70</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>232.10M</td>
<td>253.47M</td>
<td>319.52M</td>
<td>330.10M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>235.87M</td>
<td>296.19M</td>
<td>348.98M</td>
<td>337.25M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Medifast <a href="https://www.benzinga.com/quote/MED/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Medifast Q4 Earnings

Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $0.96 by 13.54 percent. The company reported quarterly sales of $191.01 million which beat the analyst consensus estimate of $184.15 million by 3.73 percent. This is a 43.36 percent decrease over sales of $337.25 million the same period last year.

Earnings Beats

Medifast Q4 2023 Adj EPS $1.09 Beats $0.96 Estimate, Sales $191.01M Beat $184.15M Estimate

ABCL

ADEA

ALLE

ANDE

AROC

AVNS

AXSM

BTCY

BYON

CAMT

CMTG

CRNT

CSGP

DBRG

DFIN

ENLC

ENVX

ESRT

ETRN

EXPD

FANG

GATO

GMED

HALO

ILPT

INST

JBGS

LAND

LGIH

MATX

MFIN

MIDD

MTDR

NXRT

QUAD

SEVN

SKWD

SMMT

SPNS

SPNT

TCMD

Earnings Scheduled For February 20, 2024

Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-02-20. Here's what investors need to know before the announcement.
Analysts estimate that Medifast will report an earnings per share (EPS) of $0.96. 
Medifast bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $1.06, which was followed by a 2.5% drop in the share price the next day.
Here's a look at Medifast's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.06</td>
<td>1.44</td>
<td>2.40</td>
<td>2.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.12</td>
<td>2.77</td>
<td>3.67</td>
<td>3.70</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.5%</td>
<td>-6.94%</td>
<td>-2.66%</td>
<td>-2.42%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708365667_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Medifast were trading at $51.46 as of February 15. Over the last 52-week period, shares are down 52.59%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MED/earnings">To track all earnings releases for Medifast visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Medifast's Earnings

<h3>The Meaning Behind Value Stocks</h3>
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock. 
<h2>The following stocks are considered to be notable value stocks in the consumer cyclical sector:</h2>
<ol>
<li>Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) - P/E: 5.11</li>
<li>PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) - P/E: 9.02</li>
<li>Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) - P/E: 9.04</li>
<li>Honda Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) - P/E: 8.99</li>
<li>Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPR#NYSE">EXPR</a>) - P/E: 0.07</li>
</ol>
This quarter, Medifast experienced a decrease in earnings per share, which was $2.77 in Q2 and is now $2.12. Most recently, the company reported a dividend yield of 8.2%, which has decreased by 0.01% from last quarter's yield of 8.21%.
Most recently, PulteGroup reported earnings per share at $3.28, whereas in Q3 earnings per share sat at $2.9. The company's most recent dividend yield sits at 0.77%, which has decreased by 0.15% from 0.92% last quarter. 
Under Armour saw a decrease in earnings per share from 0.24 in Q2 to $0.19 now. Honda Motor Co's earnings per share for Q3 sits at $1.06, whereas in Q2, they were at 1.07. The company's most recent dividend yield sits at 6.65%, which has increased by 1.63% from 5.02% last quarter. 
Most recently, Express reported earnings per share at $-9.83, whereas in Q2 earnings per share sat at $-9.05. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

EXPR

Overview Of Value Stocks In The Consumer Cyclical Sector

Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) has outperformed the market over the past 15 years by 1.79% on an annualized basis producing an average annual return of 14.06%. Currently, Medifast has a market capitalization of $596.48 million. 
Buying $100 In MED: If an investor had bought $100 of MED stock 15 years ago, it would be worth $682.73 today based on a price of $54.76 for MED at the time of writing.
<h3>Medifast's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1706898614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Medifast Stock In The Last 15 Years

Shares of Despegar.com, Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/desp#NYSE">DESP</a>) rose sharply during Wednesday&rsquo;s session after the company raised its FY23 financial guidance.
The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million.
Despegar.com shares gained 16.4% to $9.90 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Shattuck Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sttk#NASDAQ">STTK</a>) jumped 127.5% to $4.80 after the company announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.</li>
<li>ReShape Lifesciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rsls#NASDAQ">RSLS</a>) shares gained 63.8% to $0.4110 after the company announced it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX.</li>
<li>C4 Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cccc#NASDAQ">CCCC</a>) shares jumped 59% to $3.7199 after the company announced data from the CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma. Following the update, Stifel analyst Bradley Canino upgraded C4 Therapeutics from Hold to Buy and raised the price target from $2 to $12.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares gained 38.3% to $0.2016 after declining 9% on Tuesday.</li>
<li>Innovative International Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ioac#NASDAQ">IOAC</a>) shares rose 36% to $11.66.</li>
<li>NextPlay Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtp#NASDAQ">NXTP</a>) shares gained 26% to $1.1708 after surging 29% on Tuesday.</li>
<li>Nephros, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neph#NASDAQ">NEPH</a>) rose 23% to $3.16.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) gained 21.7% to $5.95 after the company announced results for MitoCareX Bio with its drug discovery platform.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eose#NASDAQ">EOSE</a>) rose 21% to $1.35. Eos Energy and Pine Gate Renewables announced partnership expansion with a minimum additional volume Of 500MWH.</li>
<li>Photronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plab#NASDAQ">PLAB</a>) gained 18.7% to $25.66 following fourth-quarter results.</li>
<li>Mynaric AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/myna#NASDAQ">MYNA</a>) shares surged 18.2% to $5.66 after the company received a $33 million order from Northrop Grumman.</li>
<li>QuantaSing Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsg#NASDAQ">QSG</a>) rose 17.2% to $2.4380 following first-quarter results.</li>
<li>Professional Diversity Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipdn#NASDAQ">IPDN</a>) gained 16% to $2.8899.</li>
<li>Aurora Mobile Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jg#NASDAQ">JG</a>) shares gained 14% to $2.8254. Aurora Mobile said its subsidiary Wuhan SendCloud Technology Co., Ltd. has entered into a strategic partnership with Beijing Muhua Information Technology Co., Ltd.</li>
<li>ABM Industries Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>) surged 13.6% to $50.38 after the company reported better-than-expected fourth-quarter financial results and issued guidance.</li>
<li>LQR House Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqr#NASDAQ">LQR</a>) rose 9.5% to $1.4126. LQR House announced its new marketing campaign for Soda Jerk.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) gained 7.4% to $384.03 after the company announced results from its Phase 2 study of VX-548 for the treatment of painful diabetic peripheral neuropathy.</li>
<li>REV Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/revg#NYSE">REVG</a>) gained 7.3% to $18.31 following upbeat quarterly results.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) rose 6.3% to $51.96. Cal-Maine has temporarily ceased production at a facility in Kansas following an outbreak of avian influenza at the site.</li>
<li>Take-Two Interactive Software, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttwo#NASDAQ">TTWO</a>) shares rose 3.5% to $162.64. Take-Two will be added to the Nasdaq-100 Index, effective prior to market open on Monday, Dec. 18, 2023.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Hywin Holdings Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hyw#NASDAQ">HYW</a>) shares fell 46.6% to $3.0001.</li>
<li>Boqii Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bq#NYSE">BQ</a>) declined 33.3% to $0.6670.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) fell 32.2% to $0.5497 as the company announced outcomes from meeting with the FDA regarding the company&#39;s next Phase 2 study supporting the advancement of next generation capecitabine for cancer patients.</li>
<li>Loop Media, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lptv#NASDAQ">LPTV</a>) fell 28.3% to $0.9246 following fourth-quarter results.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) declined 27% to $0.1415. TC BioPharm announced plan to implement ADS ratio change.</li>
<li>SRIVARU Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/svmh#NASDAQ">SVMH</a>) fell 25.5% to $0.3051.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/whlr#NASDAQ">WHLR</a>) fell 24.6% to $0.2637.</li>
<li>Green Giant Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gge#NASDAQ">GGE</a>) fell 18.8% to $0.0690. Green Giant recently announced pricing of its public offering.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wlgs#NASDAQ">WLGS</a>) fell 16.2% to $0.46 after gaining 7% on Tuesday.</li>
<li>Blackboxstocks Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blbx#NASDAQ">BLBX</a>) fell 15.8% to $3.24. Blackboxstocks announced it executed a definitive agreement to acquire Evtec Aluminium Limited.</li>
<li>IN8bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) shares fell 10.8% to $1.46 after jumping 28% on Tuesday. IN8bio recently announced updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies.</li>
<li>Target Hospitality Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/th#NYSE">TH</a>) declined 11% to $9.74 as the company lowered its FY23 guidance.</li>
<li>Medifast, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/med#NYSE">MED</a>) fell 9% to $68.66. LifeMD announced a strategic alliance with Medifast to offer transformative weight management solution.</li>
<li>Pfizer Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) declined 8.8% to $26.07 after the company provided FY24 guidance.</li>
<li>JetBlue Airways Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jblu#NASDAQ">JBLU</a>) fell 6.2% to $5.20.</li>
<li>Southwest Airlines Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/luv#NYSE">LUV</a>) fell 6% to $28.51. Southwest Airlines sees fourth-quarter unit revenues to be down 9%-10% vs. prior view of down 9%-11%.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/23/12/36196130/dont-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accurat"> Don&#39;t Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street&#39;s Most Accurate Analysts</a>

Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Virtual primary care services provider&nbsp;LifeMD Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lfmd#NASDAQ">LFMD</a>) announced a strategic alliance with&nbsp;Medifast Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/med#NYSE">MED</a>), the health and wellness company known for its habit-based and coach-guided&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/g36212244/lifemd-and-medifast-partner-to-offer-transformative-weight-management-solution" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">lifestyle solution&nbsp;OPTAVIA</a>.&nbsp;
As part of the agreement, Medifast has invested $20 million into LifeMD, including $10 million in contributions to support the collaboration, funding enhancements to the LifeMD platform, operations, and infrastructure, and a $10 million purchase of LifeMD&#39;s shares.
Medifast discontinues quarterly cash dividends,&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/b36212252/medifast-initiates-business-transformation-by-entering-the-medically-supported-weight-loss-market-" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">effective immediately</a>.
&quot;Discontinuing the dividend provides the flexibility needed to continue evolving our model as we enter an exciting new chapter for our independent&nbsp;OPTAVIA Coaches, customers, employees, and stockholders,&quot; said Dan Chard, Chairman and CEO of Medifast.
Under the terms of the agreement, Medifast will utilize LifeMD&#39;s virtual care technology platform to provide&nbsp;OPTAVIA Clients access to a clinically supported weight management program, including GLP-1 medications.
This collaboration further establishes LifeMD in a market projected to reach $100 billion by 2030.&nbsp;
In addition, LifeMD can offer its patients an independent&nbsp;OPTAVIA Coach and other lifestyle support services as part of its weight management program.
Medifast and LifeMD agreed to collaborate following a pilot program focused on providing personalized support centered on holistic health rather than weight loss alone.&nbsp;
OPTAVIA offers products and a framework for habit creation reinforced by 47,100 active earning coaches.
Price Action:&nbsp;LFMD shares are down 6.30% at $7.59, while MED stock is down 11.7% at $66.59 on the last check Wednesday.

Equities

Health Care

Contracts

General

LFMD

Why Is Wellness Company Medifast Stock Trading Lower Today?

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 40 points on Wednesday.
Shares of Pfizer Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) shares fell sharply during Wednesday&rsquo;s session after the company provided FY24 guidance.
For FY24, the pharma giant expects revenue of $58.5 billion-$61.5 billion, including the expected contribution from the Seagen acquisition versus the consensus of $63.17 billion. The company forecasts FY24 adjusted diluted EPS guidance of $2.05-$2.25, including the expected impact of the Seagen acquisition, compared to the consensus of $3.17.
Pfizer shares tumbled 8.8% to $26.07 on Wednesday.
Here are some other big stocks recording losses in today&rsquo;s session.
<ul>
<li>Target Hospitality Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/th#NYSE">TH</a>) shares fell 11% to $9.74 as the company lowered its FY23 guidance.</li>
<li>Medifast, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/med#NYSE">MED</a>) dipped 9% to $68.66. LifeMD announced a strategic alliance with Medifast to offer transformative weight management solution.</li>
<li>Unisys Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uis#NYSE">UIS</a>) fell 6.7% to $4.97.</li>
<li>JetBlue Airways Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jblu#NASDAQ">JBLU</a>) dipped 6.2% to $5.20.</li>
<li>Southwest Airlines Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/luv#NYSE">LUV</a>) shares declined 6% to $28.51. Southwest Airlines sees fourth-quarter unit revenues to be down 9%-10% vs. prior view of down 9%-11%.</li>
<li>Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) fell 5% to $74.15. Moderna recently announced changes to its operating model to bring focus to its short- and long-term business goals.</li>
<li>BioNTech SE (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bntx#NASDAQ">BNTX</a>) fell 4.8% to $93.90.</li>
<li>XPeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) fell 4.7% to $14.81. XPeng Inc. 13D(amended) filing showed Alibaba Group Holding Limited reported a 12.5% stake in the co as of Dec. 6, 2023.</li>
<li>Paramount Global (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/paraa#NASDAQ">PARAA</a>) fell 4.5% to $19.64.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36216655/bitcoin-ethereum-fall-ahead-of-fed-decision-bonk-becomes-top-loser"> Bitcoin, Ethereum Fall Ahead Of Fed Decision; Bonk Becomes Top Loser</a>

BNTX

MRNA

PARAA

XPEV

Pfizer Issues FY24 Forecast, Joins Target Hospitality, Southwest Airlines And Other Big Stocks Moving Lower On Wednesday

LifeMD And Medifast Partner To Offer Transformative Weight Management Solution

Outlook
The company expects full-year 2023 revenue to be in the range of $1,050 million to $1,070 million and full-year 2023 diluted EPS to be in the range of $8.65 to $9.55. The full-year 2023 earnings guidance assumes a 20.5% to 21.5% effective tax rate.

Medifast Sees FY23 EPS $8.65-$9.55 Vs $8.52 Est.; Revenue $1.05B-$1.07B Vs $1.09B Est.; Guidance Assumes A 20.5%-21.5% Effective Tax Rate

Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) reported quarterly earnings of $2.12 per share which beat the analyst consensus estimate of $1.06 by 100 percent. This is a 36.14 percent decrease over earnings of $3.32 per share from the same period last year. The company reported quarterly sales of $235.87 million which beat the analyst consensus estimate of $232.10 million by 1.62 percent. This is a 39.58 percent decrease over sales of $390.40 million the same period last year.

Medifast Q3 2023 Adj EPS $2.12 Beats $1.06 Estimate, Sales $235.87M Beat $232.10M Estimate

Medifast Is Getting Attractive

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One tool that bargain hunters can utilize to identify beaten up <a href="https://www.investopedia.com/ask/answers/04/052704.asp">stocks to buy after significant declines</a> is the relative strength index (<a href="https://investorplace.com/stock-quotes/rsi-stock-quote/">RSI</a>). The RSI signals when a stock&rsquo;s downward momentum may be exhausted, indicating that a correction could provide <a href="https://medium.com/@unschooledtrader/unleashing-the-power-of-rsi-an-in-depth-manual-for-trading-with-relative-strength-index-e7ad4682b2d3#:~:text=RSI%20values%20above%2070%20are,selling%20opportunities%20in%20the%20market.">upside potential</a>.



Typically, an <a href="https://fastercapital.com/topics/interpreting-overbought-and-oversold-conditions-with-rsi.html">RSI reading below 30</a> is viewed as an &lsquo;oversold&rsquo; level, suggesting the asset may be due to a rebound. However, the RSI alone is insufficient to conclude a buying opportunity exists in beaten up stocks to buy. A thorough review of the company&rsquo;s financial position is prudent to <a href="https://www.investopedia.com/terms/v/valuation.asp">evaluate whether value currently exists</a>.



The following three stocks have seen their share prices decline substantially recently. Although their RSIs indicate oversold conditions, their underlying business fundamentals still appear sound. This provides a potential for short-term gains for investors looking for certain beaten up stocks to buy.



<h2>Albertsons (ACI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/shutterstock_2146418893-300x169.jpg" alt="ACI stock: the Albertsons logo on the side of a building."><div>Source: Tada Images / Shutterstock</div></div>Albertsons (NYSE:<a href="https://investorplace.com/stock-quotes/aci-stock-quote/">ACI</a>) has been heavily featured in the news lately, largely due to <a href="https://www.reuters.com/markets/deals/kroger-acquire-rival-albertsons-near-25-billion-deal-2022-10-14/">Kroger&rsquo;s proposed merger</a> announced in October 2022. However, <a href="https://www.reuters.com/markets/deals/kroger-albertsons-25-billion-merger-fraught-with-roadblocks-2024-02-26/">the deal has faced significant obstacles</a>. Recently, the FTC filed a <a href="https://finance.yahoo.com/news/next-kroger-albertsons-merger-case-103430523.html">lawsuit that has placed the merger&rsquo;s fate</a> in the hands of the judiciary. This has unsettled investors, sending the ACI lower to its <a href="https://www.marketbeat.com/market-data/oversold-stocks-rsi/">14-day RSI of 11.6</a>.



While a successful consummation of the Kroger deal could deliver substantial upside, Albertsons maintains robust financials even without the merger. Its latest Q3 earnings demonstrated this resiliency, with <a href="https://www.albertsonscompanies.com/newsroom/press-releases/news-details/2024/Albertsons-Companies-Inc.-Reports-Third-Quarter-Fiscal-2023-Results/default.aspx">diluted EPS jumping over 300%</a>. Due to its undervaluation and strong fundamentals, ACI could be considered one of the beaten up stocks to buy.



Albertsons trades at a relatively low valuation, with a <a href="https://finance.yahoo.com/quote/ACI?.tsrc=fin-srch">price-to-earnings (P/E) ratio of just 8.7x </a>&ndash; less than <a href="https://stockanalysis.com/stocks/industry/grocery-stores/">half the broader U.S. grocery sector at 17.2x</a>. This leaves the stock undervalued, representing one of the more compelling beaten up stocks to buy for patient investors.&#8203;



<h2>Medifast (MED)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png" alt="Light blue pills on white background. Pharmaceutical industry, medical treatment, presciption drugs concept. Digital 3D render., biotech stocks, big pharma. EVAX stock"><div>Source: Hernan E. Schmidt / Shutterstock.com</div></div>Medifast (NYSE:<a href="https://investorplace.com/stock-quotes/med-stock-quote/">MED</a>) has been facing some headwinds lately. The weight loss and supplement company suffered from consumers&rsquo; ability to hire weight loss coaches and the arrival of Ozempic and other drugs. The most <a href="https://finance.yahoo.com/news/medifast-full-2023-earnings-eps-105236371.html">recent earnings missed expectations</a>, weighing heavily on the price of this beaten up stock to buy. Management remains <a href="https://ir.medifastinc.com/2023-12-13-Medifast-Initiates-Business-Transformation-by-Entering-the-Medically-Supported-Weight-Loss-Market-through-Collaboration-with-LifeMD,-a-Virtual-Primary-Care-Provider,-and-Adjusting-its-Capital-Allocation-Policy">hopeful of a turnaround</a> following a deal with LifeMD (NASDAQ:<a href="https://investorplace.com/stock-quotes/lfmd-stock-quote/">LFMD</a>) to expand sales channels.



The company&rsquo;s shares dropped significantly, with its RSI reaching an oversold level of just 5.9. What&rsquo;s interesting for potential investors is that Medifast trades at a P/E ratio of only 4.2x despite the earnings miss. The forward dividend yield stands at 17.4%, and the company increased its cash holdings. This indicates that the dividend is well covered and provides attractive value for investors in this beaten-up stock.



<h2>Apple (AAPL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/09/aapl1600-300x169.png" alt="Apple (AAPL) logo brand and text sign on entrance facade store American multinational boutique corporation dealership shop. Apple Layoffs"><div>Source: sylv1rob1 / Shutterstock.com</div></div>Even major technology firms are not immune to market volatility, as Apple (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>)&nbsp;shareholders are now well aware. The iPhone maker experienced a difficult beginning in 2024 as <a href="https://finance.yahoo.com/news/apple-looks-most-oversold-years-162621064.html">sales in China and across the EU fell short</a> of expectations. Apple&rsquo;s stock price has dropped 12% this year, placing the company &ndash; a long-term favorite of Warren Buffett &ndash; in its most oversold position in six years at an <a href="https://www.profitspi.com/stock/view.aspx?v=stock-chart&amp;p=AAPL&amp;uv=100563">RSI of just 22.1</a>.



While a business as large and well-established as Apple may not immediately spring to mind when considering beaten up stocks to buy, technical analysts note the current weakness presents investors with a potential buying opportunity to secure a high-quality business at a temporarily discounted valuation. Only time will tell if 2024 brings an uptick in fortunes for the technology titan. However, long-term backers will hope current headwinds prove a mere blip rather than the start of a longer-term downtrend.&#8203;



<a href="https://finance.yahoo.com/quote/AAPL?.tsrc=fin-srch">Apple&rsquo;s P/E ratio trades at just 26.3x</a>, <a href="https://www.multpl.com/s-p-500-pe-ratio">below the S&amp;P 500&lsquo;s 27.7x</a>. Investors may see the beaten up stock to buy as a good quality choice that will shine through in the longer run.



On the date of publication, Stavros Tousios did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Stavros Tousios, MBA, is the founder and chief analyst at Markets Untold. With expertise in FX, macros, equity analysis, and investment advisory, Stavros delivers investors strategic guidance and valuable insights.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/hey-bottom-fishers-3-beaten-up-stocks-to-buy-for-short-term-gains/">Hey, Bottom Fishers! 3 Beaten Up Stocks to Buy for Short-Term Gains</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Hey, Bottom Fishers! 3 Beaten Up Stocks to Buy for Short-Term Gains

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
With the growing demand for telemedicine, the market could be worth about&nbsp;<a href="https://www.pymnts.com/healthcare/2023/telemedicine-market-projected-to-reach-450-billion-by-2032/">$450 billion </a>by the time 2032 rolls around. That&rsquo;s according to Emergen Research. By 2034, it could&nbsp;<a href="https://finance.yahoo.com/news/telehealth-market-boost-usd-888-231000787.html">hit $888.1 billion</a>, says Prophecy Market Insights. All creating big opportunities for telemedicine stocks.



First made popular during the pandemic, it&rsquo;s become a much-needed fixture for a lot of patients who just don&rsquo;t want to drive to the doctor or sit in the waiting room. Unless there&rsquo;s a medical emergency that requires a doctor visit, patients can get prescriptions, treatment recommendations or even have their vitals checked with connected medical devices.&nbsp;



Telehealth platforms are even great for visits with mental health professionals. For example,&nbsp;<a href="https://mhealthintelligence.com/news/telehealth-use-remains-high-in-mental-health-infectious-disease-care#:~:text=Mental%20health%20has%20continued%20to,and%20transplant%20(10%20percent).">according to mHealth Intelligence</a>, &ldquo;Digital mental health visits are also among trends in telemedicine as they rank highest among the specialties in 2023. According to statistics, by the third quarter of 2023,&nbsp;37% of mental health visits&nbsp;took place virtually, followed by infectious disease, obstetrics and transplant.&rdquo;



While I personally like to visit my doctor for a more thorough examination, millions of people are opting for telehealth care. And until that trend dies off, investors may want to seriously consider top telemedicine stocks such as:



<h2>LifeMD (LFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/telehealth1600-300x169.jpg" alt="A woman in a wicker chair looking at a doctor on a tablet, chatting. telehealth stocks"><div>Source: Agenturfotografin/ShutterStock.com</div></div>Let&rsquo;s start with telehealth company&nbsp;LifeMD&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lfmd-stock-quote/">LFMD</a>), which has been one of the most explosive telemedicine stocks on the market.



Since bottoming out around $5 earlier this year, LFMD is now up to $8.90. From here, if it can break above resistance, I&rsquo;d like to see it closer to $15, near-term.&nbsp;



Helping,&nbsp;<a href="https://www.globenewswire.com/news-release/2023/12/13/2795365/0/en/LifeMD-and-Medifast-Partner-to-Offer-Transformative-Weight-Management-Solution.html">LFMD recently partnered</a>&nbsp;with&nbsp;Medifast&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/med-stock-quote/">MED</a>). Under the agreement, Medifast will use LFMD&rsquo;s virtual care technology to provide some of its clients with a clinically supported weight management program, including GLP-1 medications.&nbsp;



Investors loved the news because it further exposes LFMD to a&nbsp;<a href="https://www.globenewswire.com/news-release/2023/12/13/2795365/0/en/LifeMD-and-Medifast-Partner-to-Offer-Transformative-Weight-Management-Solution.html">potential $100 billion</a>&nbsp;weight loss market by 2030, as noted in a recent company press release.&nbsp;



Even better, LFMD knocked earnings out of the park. In its fourth quarter, its EPS jumped to 15 cents, which beat by 12 cents. Revenue &mdash; up about 60% year over year &mdash; came in at $44.86 million, which beat by $4.37 million. This year, &ldquo;Revenue to be at least $200 million reflecting performance to date in our GLP-1 weight management program exceeding previous guidance, raised from previous guidance of $195 million to $205 million,&rdquo;&nbsp;<a href="https://finance.yahoo.com/news/lifemd-reports-fourth-quarter-2023-200500526.html#:~:text=As%20a%20result%20of%20the,of%20%24195%20to%20%24205%20million.">added the company</a>.



<h2>Hims &amp; Hers Health (HIMS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/hims-stock-1-300x169.jpg" alt="The logo for Hims &amp; Hers (HIMS) displayed on a smartphone screen."><div>Source: Lori Butcher / Shutterstock.com</div></div>There is also&nbsp;Hims &amp; Hers Health&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/hims-stock-quote/">HIMS</a>), a telehealth company that sells prescriptions and over-the-counter medications online.&nbsp;



Over the last few weeks, HIMS exploded from about $9.50 to a high of $15.12. All after issuing impressive fourth quarter and full-year 2024 guidance.



It also now expects to see Q1 revenue of $267 million to $272 million, which is above expectations for $252.84 million. For the full-year, it now expects to see $1.17 billion to $1.2 billion in revenue, which is above estimates for $1.11 billion.



Even more impressive,&nbsp;<a href="https://seekingalpha.com/article/4665872-unlocking-growth-why-hims-and-hers-stock-is-a-very-compelling-buy-in-2024">as noted by Seeking Alpha</a>, &ldquo;According to&nbsp;Precedence Research, the U.S. Health &amp; Wellness market &ndash; the broad sector in which HIMS operates &ndash; achieved a valuation of $1.2 trillion in 2022 and is anticipated to exhibit a compound annual growth rate of ~6% through 2026, reaching $1.5 trillion.&rdquo;



And,&nbsp;<a href="https://finance.yahoo.com/news/hims-hers-health-inc-reports-210500390.html">as noted by co-founder and CEO Andrew Dudum</a>: &ldquo;In 2024, we expect to eclipse $1 billion in revenue and deliver our first full year of net income profitability through a continued focus on building personalized and accessible treatments in each of our core specialties. We believe this approach will meaningfully break down barriers that keep individuals from seeking treatment, which will allow us to bring these unique offerings to tens of millions of subscribers over time.&rdquo;



<h2>Global X Telemedicine &amp; Digital Health ETF (EDOC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div>Or, if you want to diversify with top telemedicine at less cost, there&rsquo;s the&nbsp;Global X Telemedicine &amp; Digital Health ETF&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/edoc-stock-quote/">EDOC</a>).&nbsp;



<a href="https://www.globalxetfs.com/funds/edoc/">With an expense ratio of 0.68%,</a>&nbsp;the $9.50 per share ETF invests in telemedicine, healthcare analytics, connected healthcare devices and administrative digitization-related stocks. Some of its top holdings include&nbsp;Dexcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>),&nbsp;Illumina&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ilmn-stock-quote/">ILMN</a>), Hims &amp; Hers Health, and&nbsp;Tandem Diabetes&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) to name a few of its 37 holdings.



With telemedicine and wearables monitoring, the sector could get quite big. In fact,&nbsp;<a href="https://www.globalxetfs.com/funds/edoc/">according to Global X ETFs</a>, &ldquo;Following success in diabetic monitoring, wearables are expanding into cardiovascular care. The potential market could be enormous, as an estimated 33mm people have atrial fibrillation&nbsp;and some 1.28bn adults have hypertension.&rdquo;&nbsp;



&ldquo;The global telemedicine market increased over 8% from 2022 to 2023, exceeding $94bn. Forecasts suggest the market could reach over $286bn by 2028,&rdquo;&nbsp;<a href="https://www.globalxetfs.com/funds/edoc/">they added</a>. The site also noted that artificial intelligence could be another key catalyst for telemedicine growth.



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral">Publishing Guidelines.</a>
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/3-stocks-that-could-benefit-from-the-rise-of-telemedicine/">3 Stocks That Could Benefit from the Rise of Telemedicine</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Stocks That Could Benefit from the Rise of Telemedicine

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
With the growing demand for telemedicine, the market could be worth about&nbsp;<a href="https://www.pymnts.com/healthcare/2023/telemedicine-market-projected-to-reach-450-billion-by-2032/">$450 billion </a>by the time 2032 rolls around. That&rsquo;s according to Emergen Research. By 2034, it could&nbsp;<a href="https://finance.yahoo.com/news/telehealth-market-boost-usd-888-231000787.html">hit $888.1 billion</a>, says Prophecy Market Insights. All creating big opportunities for telemedicine stocks.



First made popular during the pandemic, it&rsquo;s become a much-needed fixture for a lot of patients who just don&rsquo;t want to drive to the doctor or sit in the waiting room. Unless there&rsquo;s a medical emergency that requires a doctor visit, patients can get prescriptions, treatment recommendations or even have their vitals checked with connected medical devices.&nbsp;



Telehealth platforms are even great for visits with mental health professionals. For example,&nbsp;<a href="https://mhealthintelligence.com/news/telehealth-use-remains-high-in-mental-health-infectious-disease-care#:~:text=Mental%20health%20has%20continued%20to,and%20transplant%20(10%20percent).">according to mHealth Intelligence</a>, &ldquo;Digital mental health visits are also among trends in telemedicine as they rank highest among the specialties in 2023. According to statistics, by the third quarter of 2023,&nbsp;37% of mental health visits&nbsp;took place virtually, followed by infectious disease, obstetrics and transplant.&rdquo;



While I personally like to visit my doctor for a more thorough examination, millions of people are opting for telehealth care. And until that trend dies off, investors may want to seriously consider top telemedicine stocks such as:



<h2>LifeMD (LFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/telehealth1600-300x169.jpg" alt="A woman in a wicker chair looking at a doctor on a tablet, chatting. telehealth stocks"><div>Source: Agenturfotografin/ShutterStock.com</div></div>Let&rsquo;s start with telehealth company&nbsp;LifeMD&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lfmd-stock-quote/">LFMD</a>), which has been one of the most explosive telemedicine stocks on the market.



Since bottoming out around $5 earlier this year, LFMD is now up to $8.90. From here, if it can break above resistance, I&rsquo;d like to see it closer to $15, near-term.&nbsp;



Helping,&nbsp;<a href="https://www.globenewswire.com/news-release/2023/12/13/2795365/0/en/LifeMD-and-Medifast-Partner-to-Offer-Transformative-Weight-Management-Solution.html">LFMD recently partnered</a>&nbsp;with&nbsp;Medifast&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/med-stock-quote/">MED</a>). Under the agreement, Medifast will use LFMD&rsquo;s virtual care technology to provide some of its clients with a clinically supported weight management program, including GLP-1 medications.&nbsp;



Investors loved the news because it further exposes LFMD to a&nbsp;<a href="https://www.globenewswire.com/news-release/2023/12/13/2795365/0/en/LifeMD-and-Medifast-Partner-to-Offer-Transformative-Weight-Management-Solution.html">potential $100 billion</a>&nbsp;weight loss market by 2030, as noted in a recent company press release.&nbsp;



Even better, LFMD knocked earnings out of the park. In its fourth quarter, its EPS jumped to 15 cents, which beat by 12 cents. Revenue &mdash; up about 60% year over year &mdash; came in at $44.86 million, which beat by $4.37 million. This year, &ldquo;Revenue to be at least $200 million reflecting performance to date in our GLP-1 weight management program exceeding previous guidance, raised from previous guidance of $195 million to $205 million,&rdquo;&nbsp;<a href="https://finance.yahoo.com/news/lifemd-reports-fourth-quarter-2023-200500526.html#:~:text=As%20a%20result%20of%20the,of%20%24195%20to%20%24205%20million.">added the company</a>.



<h2>Hims &amp; Hers Health (HIMS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/hims-stock-1-300x169.jpg" alt="The logo for Hims &amp; Hers (HIMS) displayed on a smartphone screen."><div>Source: Lori Butcher / Shutterstock.com</div></div>There is also&nbsp;Hims &amp; Hers Health&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/hims-stock-quote/">HIMS</a>), a telehealth company that sells prescriptions and over-the-counter medications online.&nbsp;



Over the last few weeks, HIMS exploded from about $9.50 to a high of $15.12. All after issuing impressive fourth quarter and full-year 2024 guidance.



It also now expects to see Q1 revenue of $267 million to $272 million, which is above expectations for $252.84 million. For the full-year, it now expects to see $1.17 billion to $1.2 billion in revenue, which is above estimates for $1.11 billion.



Even more impressive,&nbsp;<a href="https://seekingalpha.com/article/4665872-unlocking-growth-why-hims-and-hers-stock-is-a-very-compelling-buy-in-2024">as noted by Seeking Alpha</a>, &ldquo;According to&nbsp;Precedence Research, the U.S. Health &amp; Wellness market &ndash; the broad sector in which HIMS operates &ndash; achieved a valuation of $1.2 trillion in 2022 and is anticipated to exhibit a compound annual growth rate of ~6% through 2026, reaching $1.5 trillion.&rdquo;



And,&nbsp;<a href="https://finance.yahoo.com/news/hims-hers-health-inc-reports-210500390.html">as noted by co-founder and CEO Andrew Dudum</a>: &ldquo;In 2024, we expect to eclipse $1 billion in revenue and deliver our first full year of net income profitability through a continued focus on building personalized and accessible treatments in each of our core specialties. We believe this approach will meaningfully break down barriers that keep individuals from seeking treatment, which will allow us to bring these unique offerings to tens of millions of subscribers over time.&rdquo;



<h2>Global X Telemedicine &amp; Digital Health ETF (EDOC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div>Or, if you want to diversify with top telemedicine at less cost, there&rsquo;s the&nbsp;Global X Telemedicine &amp; Digital Health ETF&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/edoc-stock-quote/">EDOC</a>).&nbsp;



<a href="https://www.globalxetfs.com/funds/edoc/">With an expense ratio of 0.68%,</a>&nbsp;the $9.50 per share ETF invests in telemedicine, healthcare analytics, connected healthcare devices and administrative digitization-related stocks. Some of its top holdings include&nbsp;Dexcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/">DXCM</a>),&nbsp;Illumina&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ilmn-stock-quote/">ILMN</a>), Hims &amp; Hers Health, and&nbsp;Tandem Diabetes&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) to name a few of its 37 holdings.



With telemedicine and wearables monitoring, the sector could get quite big. In fact,&nbsp;<a href="https://www.globalxetfs.com/funds/edoc/">according to Global X ETFs</a>, &ldquo;Following success in diabetic monitoring, wearables are expanding into cardiovascular care. The potential market could be enormous, as an estimated 33mm people have atrial fibrillation&nbsp;and some 1.28bn adults have hypertension.&rdquo;&nbsp;



&ldquo;The global telemedicine market increased over 8% from 2022 to 2023, exceeding $94bn. Forecasts suggest the market could reach over $286bn by 2028,&rdquo;&nbsp;<a href="https://www.globalxetfs.com/funds/edoc/">they added</a>. The site also noted that artificial intelligence could be another key catalyst for telemedicine growth.



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral">Publishing Guidelines.</a>
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/3-stocks-that-could-benefit-from-the-rise-of-telemedicine/">3 Stocks That Could Benefit from the Rise of Telemedicine</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FSTA: Consumer Staples Sector Dashboard For March

68 Graham Value Stocks, 57 Fit To Buy In March

Medifast: Cheap Valuation, Uncertain Future

DGI For The DIY: 2023 Dividend Portfolio Review

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Medifast Stock (NYSE:MED), Trade Ideas